Correction: Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program
- PMID: 28211356
- DOI: 10.1158/1078-0432.CCR-16-2920
Correction: Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program
Erratum for
-
Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.Clin Cancer Res. 2015 Feb 15;21(4):819-32. doi: 10.1158/1078-0432.CCR-14-2572. Epub 2014 Dec 10. Clin Cancer Res. 2015. PMID: 25500058 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
